On August 26, EVEREST MED rose 5.16% in regular trading, trading at HK$38.88/share, with turnover of HK$68.90 million. The stock continues its upward trajectory following a multi-day rally driven by dual catalysts.

The ongoing strength follows Moderna and Merck's announcement of positive Phase III results for their mRNA personalized cancer vaccine intismeran autogene, which triggered a sector-wide re-rating of mRNA-related biotech names. EVEREST MED, which possesses an end-to-end mRNA technology platform and is developing personalized tumor vaccines EVM16 and off-the-shelf vaccine EVM14, has been a primary beneficiary.

Simultaneously, the company reported H1 revenue of RMB 1.148 billion, up 157% year-over-year, achieving profitability with adjusted net profit of RMB 97.23 million. Core product Nefecon generated RMB 889 million in sales, with net sales up 94% on expanded hospital coverage. BOCOM International maintained a Buy rating with a HK$66 target price, citing strong BD execution and validated commercialization infrastructure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)